drugset
drugset / Trial / NCT04645602

Merck IIT: RRP Pembro and Lenvatinib

NCT04645602 ↗

Phase 2 Recruiting 20 enrolled Yale University Eisai Inc. · collabMerck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelTreatment

Summary

This research study is studying Lenvatinib in combination with Pembrolizumab in people with human papillomavirus (HPV)-associated recurrent respiratory papillomatosis (RRP). The names of the study drugs involved in this study are: * Pembrolizumab * Lenvatinib

Timeline

Start
2025-07-18
Primary completion
2027-12
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Lenvatinib Small molecule 20 mg Oral
Subject Pembrolizumab Monoclonal antibody 200 mg Intravenous

Indications

human papilloma virus infection lung disorder recurrent respiratory papillomatosis